The DOI matches its Crossref record; 109 of the 109 references it cites were found in a registry or an index.
Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer
Open accessAbstract
The treatment goal for patients with early-stage lung cancer is cure. Multidisciplinary discussions of surgical resectability and medical operability determine the modality of definitive local treatment (surgery or radiotherapy) and the associated systemic therapies to further improve the likelihood of cure. Trial evidence supports cisplatin-based adjuvant therapy either after surgical resection or concurrently with radiotherapy. Consensus guidelines support neoadjuvant chemotherapy in lieu of adjuvant chemotherapy and carboplatin-based regimens for patients who are ineligible for cisplatin. The incorporation of newer agents, now standard for patients with stage IV lung cancer, into the curative therapy paradigm has lagged owing to inefficient trial designs, the lengthy follow-up needed to assess survival end points and a developmental focus on the advanced-stage disease setting. Surrogate end points, such as pathological response, are being studied and might shorten trial durations. In 2018, the anti-PD-L1 antibody durvalumab was approved for patients with stage III lung cancer after concurrent chemoradiotherapy. Since then, the study of targeted therapies and immunotherapies in patients with early-stage lung cancer has rapidly expanded. In this Review, we present the current considerations in the treatment of patients with early-stage lung cancer and explore the current and future state of clinical research to develop systemic therapies for non-metastatic lung cancer. The authors of this Review present the current considerations in the treatment of patients with early-stage lung cancer, discussing the critical determination of resectability by thoracic surgical oncologists and the management of both resectable and unresectable disease with a focus on systemic therapy selection. They also address innovations in drug development, trial design and efforts to identify early-stage cancers. Cisplatin-based adjuvant chemotherapy remains the standard of care for patients with resected high-risk non-metastatic non-small-cell lung cancer (NSCLC). Anti-PD-L1 therapy with durvalumab after concurrent chemotherapy and radiotherapy for unresectable or inoperable non-metastatic NSCLC improves overall survival. Osimertinib for 3 years after standard adjuvant therapy improves disease-free survival in patients with NSCLC harbouring EGFR mutations. Immunotherapy is being extensively studied in the preoperative and postoperative settings. Novel clinical trial designs are needed to accelerate advances in the treatment of patients with curable NSCLC. Cisplatin-based adjuvant chemotherapy remains the standard of care for patients with resected high-risk non-metastatic non-small-cell lung cancer (NSCLC). Anti-PD-L1 therapy with durvalumab after concurrent chemotherapy and radiotherapy for unresectable or inoperable non-metastatic NSCLC improves overall survival. Osimertinib for 3 years after standard adjuvant therapy improves disease-free survival in patients with NSCLC harbouring EGFR mutations. Immunotherapy is being extensively studied in the preoperative and postoperative settings. Novel clinical trial designs are needed to accelerate advances in the treatment of patients with curable NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21654 · Cited by 16,522
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Goldstraw, P., Chansky, K., Crowley, J., Rami-Porta, R., Asamura, H., Eberhardt, W. E. E., Nicholson, A. G., Groome, P., Mitchell, A., Bolejack, V., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.09.009 · Cited by 4,607
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
Brocken, P., van der Heijden, H. F. M., Dekhuijzen, P. N. R., Peters-Bax, L., & de Geus-Oei, L.-F. (2014) · Respiration · doi:10.1159/000347096 · Cited by 4,002
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809697 · Cited by 2,798
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer
Timmerman, R. (2010) · JAMA · doi:10.1001/jama.2010.261 · Cited by 2,532
Lung Cancer: Epidemiology, Etiology, and Prevention
Dela Cruz, C. S., Tanoue, L. T., & Matthay, R. A. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.09.001 · Cited by 2,484
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa031644 · Cited by 2,335
Postmus, P. E., Kerr, K. M., Oudkerk, M., Senan, S., Waller, D. A., Vansteenkiste, J., Escriu, C., & Peters, S. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx222 · Cited by 2,302
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099
Self-citationBradley, J. D., Paulus, R., Komaki, R., Masters, G., Blumenschein, G., Schild, S., Bogart, J., Hu, C., Forster, K., Magliocco, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71207-0 · Cited by 2,015
Bade, B. C., & Dela Cruz, C. S. (2020) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2019.10.001 · Cited by 1,911
Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
Winton, T., Livingston, R., Johnson, D., Rigas, J., Johnston, M., Butts, C., Cormier, Y., Goss, G., Inculet, R., Vallieres, E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043623 · Cited by 1,810
Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer
Wu, Y.-L., Tsuboi, M., He, J., John, T., Grohe, C., Majem, M., Goldman, J. W., Laktionov, K., Kim, S.-W., Kato, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2027071 · Cited by 1,798
The Effect of Advances in Lung-Cancer Treatment on Population Mortality
Howlader, N., Forjaz, G., Mooradian, M. J., Meza, R., Kong, C. Y., Cronin, K. A., Mariotto, A. B., Lowy, D. R., & Feuer, E. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916623 · Cited by 1,712
Garon, E. B., Hellmann, M. D., Rizvi, N. A., Carcereny, E., Leighl, N. B., Ahn, M.-J., Eder, J. P., Balmanoukian, A. S., Aggarwal, C., Horn, L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00934 · Cited by 1,163
Gadgeel, S., Rodríguez-Abreu, D., Speranza, G., Esteban, E., Felip, E., Dómine, M., Hui, R., Hochmair, M. J., Clingan, P., Powell, S. F., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03136 · Cited by 1,116
Radiation Dose–Volume Effects in the Lung
Marks, L. B., Bentzen, S. M., Deasy, J. O., Kong, F.-M. (., Bradley, J. D., Vogelius, I. S., El Naqa, I., Hubbs, J. L., Lebesque, J. V., Timmerman, R. D., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.06.091 · Cited by 1,103
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., Khodadoust, M. S., Esfahani, M. S., Liu, C. L., Zhou, L., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0716 · Cited by 1,072
Neoadjuvant checkpoint blockade for cancer immunotherapy
Topalian, S. L., Taube, J. M., & Pardoll, D. M. (2020) · Science · doi:10.1126/science.aax0182 · Cited by 1,001
Reck, M., Mok, T. S. K., Nishio, M., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30084-0 · Cited by 946
Xu, Y., Liu, H., Chen, J., & Zhou, Q. (2010) · Thoracic Cancer · doi:10.1111/j.1759-7714.2010.00016.x · Cited by 884
Provencio, M., Nadal, E., Insa, A., García-Campelo, M. R., Casal-Rubio, J., Dómine, M., Majem, M., Rodríguez-Abreu, D., Martínez-Martí, A., De Castro Carpeño, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30453-8 · Cited by 841
A Randomized Trial of Adjuvant Chemotherapy with Uracil–Tegafur for Adenocarcinoma of the Lung
Kato, H., Ichinose, Y., Ohta, M., Hata, E., Tsubota, N., Tada, H., Watanabe, Y., Wada, H., Tsuboi, M., Hamajima, N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032792 · Cited by 818
Chun, S. G., Hu, C., Choy, H., Komaki, R. U., Timmerman, R. D., Schild, S. E., Bogart, J. A., Dobelbower, M. C., Bosch, W., Galvin, J. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.1378 · Cited by 746
Travis, W. D., Asamura, H., Bankier, A. A., Beasley, M. B., Detterbeck, F., Flieder, D. B., Goo, J. M., MacMahon, H., Naidich, D., Nicholson, A. G., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.03.025 · Cited by 722
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.
(2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.05.01 · Cited by 716
Hellmann, M. D., Chaft, J. E., William, W. N., Rusch, V., Pisters, K. M. W., Kalhor, N., Pataer, A., Travis, W. D., Swisher, S. G., & Kris, M. G. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70334-6 · Cited by 646
Self-citationPaz-Ares, L., Vicente, D., Tafreshi, A., Robinson, A., Soto Parra, H., Mazières, J., Hermes, B., Cicin, I., Medgyasszay, B., Rodríguez-Cid, J., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.06.015 · Cited by 631
Shu, C. A., Gainor, J. F., Awad, M. M., Chiuzan, C., Grigg, C. M., Pabani, A., Garofano, R. F., Stoopler, M. B., Cheng, S. K., White, A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30140-6 · Cited by 623
Cascone, T., William, W. N., Weissferdt, A., Leung, C. H., Lin, H. Y., Pataer, A., Godoy, M. C. B., Carter, B. W., Federico, L., Reuben, A., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01224-2 · Cited by 618
Self-citationScagliotti, G. V. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg059 · Cited by 593
Bradley, J. D., Hu, C., Komaki, R. R., Masters, G. A., Blumenschein, G. R., Schild, S. E., Bogart, J. A., Forster, K. M., Magliocco, A. M., Kavadi, V. S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01162 · Cited by 591
Preoperative Staging of Lung Cancer with Combined PET–CT
Fischer, B., Lassen, U., Mortensen, J., Larsen, S., Loft, A., Bertelsen, A., Ravn, J., Clementsen, P., Høgholm, A., Larsen, K., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900043 · Cited by 582
Zhong, W.-Z., Wang, Q., Mao, W.-M., Xu, S.-T., Wu, L., Shen, Y., Liu, Y.-Y., Chen, C., Cheng, Y., Xu, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30729-5 · Cited by 529
Vansteenkiste, J. F., Cho, B. C., Vanakesa, T., De Pas, T., Zielinski, M., Kim, M. S., Jassem, J., Yoshimura, M., Dahabreh, J., Nakayama, H., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00099-1 · Cited by 511
Hanna, N., Neubauer, M., Yiannoutsos, C., McGarry, R., Arseneau, J., Ansari, R., Reynolds, C., Govindan, R., Melnyk, A., Fisher, W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7840 · Cited by 491
Vansteenkiste, J., De Ruysscher, D., Eberhardt, W. E. E., Lim, E., Senan, S., Felip, E., & Peters, S. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt241 · Cited by 490
End Points and United States Food and Drug Administration Approval of Oncology Drugs
Johnson, J. R., Williams, G., & Pazdur, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.072 · Cited by 479
Vokes, E. E., Herndon, J. E., Kelley, M. J., Cicchetti, M. G., Ramnath, N., Neill, H., Atkins, J. N., Watson, D. M., Akerley, W., & Green, M. R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3569 · Cited by 478
Medicine, N. L. O. (2008) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/15360280801989377 · Cited by 468
Travis, W. D., Dacic, S., Wistuba, I., Sholl, L., Adusumilli, P., Bubendorf, L., Bunn, P., Cascone, T., Chaft, J., Chen, G., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.005 · Cited by 465
Self-citationRusch, V. W., Giroux, D. J., Kraut, M. J., Crowley, J., Hazuka, M., Winton, T., Johnson, D. H., Shulman, L., Shepherd, F., Deschamps, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2826 · Cited by 457
Betticher, D. C., Hsu Schmitz, S.-F., Tötsch, M., Hansen, E., Joss, C., von Briel, C., Schmid, R. A., Pless, M., Habicht, J., Roth, A. D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.040 · Cited by 449
Self-citationSenthi, S., Lagerwaard, F. J., Haasbeek, C. J., Slotman, B. J., & Senan, S. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70242-5 · Cited by 447
Senan, S., Brade, A., Wang, L.-H., Vansteenkiste, J., Dakhil, S., Biesma, B., Martinez Aguillo, M., Aerts, J., Govindan, R., Rubio-Viqueira, B., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8824 · Cited by 433
Felip, E., Rosell, R., Maestre, J. A., Rodríguez-Paniagua, J. M., Morán, T., Astudillo, J., Alonso, G., Borro, J. M., González-Larriba, J. L., Torres, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6204 · Cited by 430
Nicholson, A. G., Chansky, K., Crowley, J., Beyruti, R., Kubota, K., Turrisi, A., Eberhardt, W. E. E., van Meerbeeck, J., Rami-Porta, R., Goldstraw, P., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.10.008 · Cited by 421
Videtic, G. M. M., Hu, C., Singh, A. K., Chang, J. Y., Parker, W., Olivier, K. R., Schild, S. E., Komaki, R., Urbanic, J. J., & Choy, H. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.07.2260 · Cited by 414
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
Gao, S., Li, N., Gao, S., Xue, Q., Ying, J., Wang, S., Tao, X., Zhao, J., Mao, Y., Wang, B., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.017 · Cited by 401
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
Pless, M., Stupp, R., Ris, H.-B., Stahel, R. A., Weder, W., Thierstein, S., Gerard, M.-A., Xyrafas, A., Früh, M., Cathomas, R., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60294-x · Cited by 390
Self-citationAssessment of Operative Risk in Patients Undergoing Lung Resection
Kearney, D. J., Lee, T. H., Reilly, J. J., DeCamp, M. M., & Sugarbaker, D. J. (1994) · Chest · doi:10.1378/chest.105.3.753 · Cited by 382
Pataer, A., Kalhor, N., Correa, A. M., Raso, M. G., Erasmus, J. J., Kim, E. S., Behrens, C., Lee, J. J., Roth, J. A., Stewart, D. J., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318247504a · Cited by 374
Tang, C., Liao, Z., Gomez, D., Levy, L., Zhuang, Y., Gebremichael, R. A., Hong, D. S., Komaki, R., & Welsh, J. W. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.04.025 · Cited by 372
Kris, M. G., Gaspar, L. E., Chaft, J. E., Kennedy, E. B., Azzoli, C. G., Ellis, P. M., Lin, S. H., Pass, H. I., Seth, R., Shepherd, F. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.4401 · Cited by 368
Self-citationThomas, M., Rübe, C., Hoffknecht, P., Macha, H. N., Freitag, L., Linder, A., Willich, N., Hamm, M., Sybrecht, G. W., Ukena, D., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70156-6 · Cited by 346
Rothschild, S. I., Zippelius, A., Eboulet, E. I., Savic Prince, S., Betticher, D., Bettini, A., Früh, M., Joerger, M., Lardinois, D., Gelpke, H., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00276 · Cited by 333
Self-citationRusch, V. W., Giroux, D. J., Kraut, M. J., Crowley, J., Hazuka, M., Johnson, D., Goldberg, M., Detterbeck, F., Shepherd, F., Burkes, R., et al. (2001) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1067/mtc.2001.112465 · Cited by 287
Hamada, C., Tanaka, F., Ohta, M., Fujimura, S., Kodama, K., Imaizumi, M., & Wada, H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.017 · Cited by 284
Speirs, C. K., DeWees, T. A., Rehman, S., Molotievschi, A., Velez, M. A., Mullen, D., Fergus, S., Trovo, M., Bradley, J. D., & Robinson, C. G. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.09.134 · Cited by 282
Radiation Dose-Volume Effects in the Esophagus
Werner-Wasik, M., Yorke, E., Deasy, J., Nam, J., & Marks, L. B. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.05.070 · Cited by 272
Zhong, W.-Z., Chen, K.-N., Chen, C., Gu, C.-D., Wang, J., Yang, X.-N., Mao, W.-M., Wang, Q., Qiao, G.-B., Cheng, Y., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00075 · Cited by 268
Douillard, J.-Y., Tribodet, H., Aubert, D., Shepherd, F. A., Rosell, R., Ding, K., Veillard, A.-S., Seymour, L., Le Chevalier, T., Spiro, S., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181c814e7 · Cited by 252
Mauguen, A., Pignon, J.-P., Burdett, S., Domerg, C., Fisher, D., Paulus, R., Mandrekar, S. J., Belani, C. P., Shepherd, F. A., Eisen, T., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70158-x · Cited by 246
Robinson, C. G., Patel, A. P., Bradley, J. D., DeWees, T., Waqar, S. N., Morgensztern, D., Baggstrom, M. Q., Govindan, R., Bell, J. M., Guthrie, T. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.5380 · Cited by 244
Shapiro, M., Swanson, S. J., Wright, C. D., Chin, C., Sheng, S., Wisnivesky, J., & Weiser, T. S. (2010) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2010.05.041 · Cited by 226
Paz-Ares, L., Spira, A., Raben, D., Planchard, D., Cho, B. C., Özgüroğlu, M., Daniel, D., Villegas, A., Vicente, D., Hui, R., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.287 · Cited by 224
Song, W.-A., Zhou, N.-K., Wang, W., Chu, X.-Y., Liang, C.-Y., Tian, X.-D., Guo, J.-T., Liu, X., Liu, Y., & Dai, W.-M. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181cd3345 · Cited by 217
Um, S.-W., Kim, H. K., Jung, S.-H., Han, J., Lee, K. J., Park, H. Y., Choi, Y. S., Shim, Y. M., Ahn, M.-J., Park, K., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000388 · Cited by 210
Preoperative Evaluation of Patients Undergoing Lung Resection Surgerya
Datta, D., & Lahiri, B. (2003) · Chest · doi:10.1378/chest.123.6.2096 · Cited by 202
Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer
Blumenthal, G. M., Bunn, P. A., Chaft, J. E., McCoach, C. E., Perez, E. A., Scagliotti, G. V., Carbone, D. P., Aerts, H. J. W. L., Aisner, D. L., Bergh, J., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.09.017 · Cited by 184
Self-citationCurrent Landscape of Targeted Therapy in Lung Cancer
Mayekar, M. K., & Bivona, T. G. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.810 · Cited by 183
Wakelee, H. A., Dahlberg, S. E., Keller, S. M., Tester, W. J., Gandara, D. R., Graziano, S. L., Adjei, A. A., Leighl, N. B., Aisner, S. C., Rothman, J. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30691-5 · Cited by 171
Parra, E. R., Villalobos, P., Behrens, C., Jiang, M., Pataer, A., Swisher, S. G., William, W. N., Zhang, J., Lee, J., Cascone, T., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0368-0 · Cited by 167
Self-citationBilliet, C., Decaluwé, H., Peeters, S., Vansteenkiste, J., Dooms, C., Haustermans, K. M., Leyn, P. D., & Ruysscher, D. D. (2013) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.08.011 · Cited by 152
Kwiatkowski, D. J., Rusch, V. W., Chaft, J. E., Johnson, B. E., Nicholas, A., Wistuba, I. I., Merritt, R., Lee, J. M., Bunn, P. A., Tang, Y., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.8503 · Cited by 146
Self-citationGovindan, R., Mandrekar, S. J., Gerber, D. E., Oxnard, G. R., Dahlberg, S. E., Chaft, J. E., Malik, S. M., Mooney, M., Abrams, J. S., Janne, P. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0354 · Cited by 130
Self-citationChaft, J. E., Rusch, V., Ginsberg, M. S., Paik, P. K., Finley, D. J., Kris, M. G., Price, K. A. R., Azzoli, C. G., Fury, M. G., Riely, G. J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31829923ec · Cited by 122
Self-citationTsujino, K., Kurata, T., Yamamoto, S., Kawaguchi, T., Kubo, A., Isa, S., Hasegawa, Y., Ou, S. I., Takada, M., & Ando, M. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182988348 · Cited by 115
Scilla, K. A., Bentzen, S. M., Lam, V. K. L., Mohindra, P., Nichols, E., Vyfhuis, M. A. L., Bhooshan, N., Feigenberg, S. J., Edelman, M. J., & Feliciano, J. L. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0443 · Cited by 113
Kenmotsu, H., Yamamoto, N., Yamanaka, T., Yoshiya, K., Takahashi, T., Ueno, T., Goto, K., Daga, H., Ikeda, N., Sugio, K., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02674 · Cited by 112
Bradbury, P. A., Sivajohanathan, D., Chan, A., Kulkarni, S., Ung, Y., & Ellis, P. M. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.07.002 · Cited by 101
Pechoux, C. L., Pourel, N., Barlési, F., Finn, C. F., Lerouge, D., Zalcman, G., Antoni, D., Lamezec, B., Nestle, U., Boisselier, P., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2280 · Cited by 94
Oberije, C., Ruysscher, D. D., Petit, S., van Meerbeeck, J. P., Vandecasteele, K., Neve, W. D., Dingemans, A. C., Naqa, I. E., Deasy, J. O., Bradley, J. D., et al. (2010) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2010.09.028 · Cited by 82
Wang, J., Olak, J., & Ferguson, M. K. (1999) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(99)70338-7 · Cited by 76
Thor, M., Deasy, J. O., Hu, C., Gore, E., Bar‐Ad, V., Robinson, C. G., Wheatley, M., Oh, J. H., Bogart, J. A., Garces, Y. I., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2627 · Cited by 73
Kohutek, Z. A., Wu, A. J.-C., Zhang, Z., Foster, A., Din, S. U., Yorke, E. D., Downey, R. J., Rosenzweig, K. E., Weber, W., & Rimner, A. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.05.019 · Cited by 67
Self-citationFrontline immunotherapy for NSCLC — the tale of the tail
Chiang, A. C., & Herbst, R. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0317-y · Cited by 57
Leeman, J. E., Rimner, A., Montecalvo, J., Hsu, M., Zhang, Z., von Reibnitz, D., Panchoo, K., Yorke, E. D., Adusumilli, P. S., Travis, W. D., et al. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.09.037 · Cited by 54
Self-citationChaft, J. E., Dunphy, M. P., Naidoo, J., Travis, W. D., Hellmann, M. D., Woo, K. M., Downey, R. J., Rusch, V. W., Ginsberg, M. S., Azzoli, C. G., et al. (2015) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.12.104 · Cited by 46
Self-citationSung, S., Son, S. H., Park, E., & Kay, C. S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173955 · Cited by 42
Pagès, P., Mariet, A., Madelaine, L., Cottenet, J., Hanna, H. A., Quantin, C., & Bernard, A. (2018) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2018.11.098 · Cited by 33
Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer
Cascone, T., Gold, K. A., Swisher, S. G., Liu, D. D., Fossella, F. V., Sepesi, B., Pataer, A., Weissferdt, A., Kalhor, N., Vaporciyan, A. A., et al. (2018) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2017.08.052 · Cited by 32
Self-citationHristov, B. D., Eguchi, T., Bains, S., Dycoco, J., Tan, K. S., Isbell, J. M., Park, B. J., Jones, D. R., & Adusumilli, P. S. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002772 · Cited by 32
Cascone, T., Sepesi, B., Lin, H. Y., Kalhor, N., Parra, E. R., Jiang, M., Godoy, M. C. B., Zhang, J., Fossella, F. V., Tsao, A. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4180 · Cited by 31
Self-citationDiminished but not dead: chemotherapy for the treatment of NSCLC
Herbst, R. S., & Sznol, M. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30524-1 · Cited by 31
Thor, M., Deasy, J. O., Iyer, A., Bendau, E. V., Fontanella, A. N., Apte, A., Yorke, E. D., Rimner, A., & Jackson, A. (2019) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2019.05.011 · Cited by 31
Self-citationPetrelli, F., & Barni, S. (2013) · Medical Oncology · doi:10.1007/s12032-013-0641-5 · Cited by 17
Liquid biopsy for ctDNA to revolutionize the care of patients with early stage lung cancers
Li, B. T., Stephens, D. P., Chaft, J. E., Rudin, C. M., Jones, D. R., Rusch, V. W., Rimner, A., & Isbell, J. M. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.09.02 · Cited by 12
Self-citationRole of MPR as an Early Signal for Efficacy in Neoadjuvant Studies
Blakely, C. M., & McCoach, C. E. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1129 · Cited by 9
Cited by
Clinical implications of T cell exhaustion for cancer immunotherapy
Chow, A., Perica, K., Klebanoff, C. A., & Wolchok, J. D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00689-z · Cited by 1,044
Carbon Dots in Bioimaging, Biosensing and Therapeutics: A Comprehensive Review
Wang, B., Cai, H., Waterhouse, G. I. N., Qu, X., Yang, B., & Lu, S. (2022) · Small Science · doi:10.1002/smsc.202200012 · Cited by 411
Vanguri, R. S., Luo, J., Aukerman, A. T., Egger, J. V., Fong, C. J., Horvat, N., Pagano, A., Araujo-Filho, J. D. A. B., Geneslaw, L., Rizvi, H., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00416-8 · Cited by 395
Lung Cancer—Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature)
Smolarz, B., Łukasiewicz, H., Samulak, D., Piekarska, E., Kołaciński, R., & Romanowicz, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052049 · Cited by 259
Metadata
- Authors
- Chaft, J. E., Rimner, A., Weder, W., Azzoli, C. G., Kris, M. G., & Cascone, T.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2021-04-28
- Volume
- 18
- Issue
- 9
- Pages
- 547-557
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W3157423185
- Cited by
- 375
- References
- 109
- FWCI
- 14.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.